Literature DB >> 15287084

A sample size computation method for non-linear mixed effects models with applications to pharmacokinetics models.

Dongwoo Kang1, Janice B Schwartz, Davide Verotta.   

Abstract

We propose a simple method to compute sample size for an arbitrary test hypothesis in population pharmacokinetics (PK) studies analysed with non-linear mixed effects models. Sample size procedures exist for linear mixed effects model, and have been recently extended by Rochon using the generalized estimating equation of Liang and Zeger. Thus, full model based inference in sample size computation has been possible. The method we propose extends the approach using a first-order linearization of the non-linear mixed effects model and use of the Wald chi(2) test statistic. The proposed method is general. It allows an arbitrary non-linear model as well as arbitrary distribution of random effects characterizing both inter- and intra-individual variability of the mixed effects model. To illustrate possible uses of the method we present tables of minimum sample sizes, in particular, with an illustration of the effect of sampling design on sample size. We demonstrate how (D-)optimal or frequent sampling requires fewer subjects in comparison to a sparse sampling design. We also present results from Monte Carlo simulations showing that the computed sample size can produce the desired power. The proposed method greatly reduces computing times compared with simulation-based methods of estimating sample sizes for population PK studies.

Mesh:

Substances:

Year:  2004        PMID: 15287084     DOI: 10.1002/sim.1695

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Sample size computations for PK/PD population models.

Authors:  Dongwoo Kang; Janice B Schwartz; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

2.  How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Eur J Clin Pharmacol       Date:  2008-05-16       Impact factor: 2.953

3.  Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug-drug interaction studies.

Authors:  Shuying Yang; Misba Beerahee
Journal:  Eur J Clin Pharmacol       Date:  2010-12-02       Impact factor: 2.953

4.  Differential activation of limbic circuitry associated with chronic ethanol withdrawal in DBA/2J and C57BL/6J mice.

Authors:  Gang Chen; Matthew T Reilly; Laura B Kozell; Robert Hitzemann; Kari J Buck
Journal:  Alcohol       Date:  2009-09       Impact factor: 2.405

Review 5.  Tenofovir alafenamide use in pregnant and lactating women living with HIV.

Authors:  Ahizechukwu C Eke; Kristina M Brooks; Rahel D Gebreyohannes; Jeanne S Sheffield; Kelly E Dooley; Mark Mirochnick
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-03-17       Impact factor: 4.936

6.  Comparing stochastic differential equations and agent-based modelling and simulation for early-stage cancer.

Authors:  Grazziela P Figueredo; Peer-Olaf Siebers; Markus R Owen; Jenna Reps; Uwe Aickelin
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

7.  Anti-Inflammatory and Anti-Rheumatic Potential of Selective Plant Compounds by Targeting TLR-4/AP-1 Signaling: A Comprehensive Molecular Docking and Simulation Approaches.

Authors:  Ashrafullah Khan; Shafi Ullah Khan; Adnan Khan; Bushra Shal; Sabih Ur Rehman; Shaheed Ur Rehman; Thet Thet Htar; Salman Khan; Sirajudheen Anwar; Ahmed Alafnan; Kannan Rr Rengasamy
Journal:  Molecules       Date:  2022-07-05       Impact factor: 4.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.